Abstract: An intraocular lens includes an optic for focusing light and a movement assembly coupled to the optic. The movement assembly is adapted to cooperate with the eye to effect accommodating movement of the optic. The movement assembly includes a plurality of movement members each with a proximal region coupled to the optic and an enlarged distal region. The enlarged distal region may be integral with the proximal region, or may be mechanically coupled thereto.

Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1

Abstract: Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention.

Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.

Abstract: Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.

Abstract: Compositions including a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye, and a carrier component in an amount effective to act as a carrier for the quinolone component are provided. The present compositions are substantially free of other components effective as preservatives. Preferably the quinolone component has fungistatic activity. In one very useful embodiment, the compositions include a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention.

Abstract: Methods for reducing non-inflammatory pain caused by injuries and traumas include administering to a mammal eye having non-inflammatory pain a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in non-inflammatory pain.

Abstract: Compositions for caring for contact lenses and eyes include a liquid aqueous medium and a vitamin derivative component present in an amount effective as a surfactant in the composition. The compositions can be used to clean, soak, re-wet and, with the inclusion of a disinfectant, disinfect contact lenses. In addition, the compositions are effective as artificial tears and eye wash solutions. Methods for contact lens care and eye care are also disclosed.

Abstract: Methods and compositions for the treatment of pain using thiourea derivatives. Particularly disclosed are new compositions for the treatment of chronic pain, and methods for their use.

Abstract: An intraocular lens implantable in an eye includes an optic for placement in the capsular bag of the eye and for directing light toward the retina of the eye. The optic has a central optical axis, an anterior face, an opposing posterior face and a peripheral edge between the faces. The peripheral edge has one or more curved or angled surfaces that reduce glare within the IOL. For instance, a rounded transition surface on the anterior side of the peripheral edge diffuses the intensity of reflected light, or a particular arrangement of straight edge surfaces refracts the light so as not to reflect, or does not reflect at all. The intersection of the peripheral edge and at least one of the anterior face and the posterior face, preferably both of such faces, forms a peripheral corner located at a discontinuity between the peripheral edge and the intersecting face or faces.

Abstract: Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.

Abstract: Methods for treating fibromyalgia may include administering a therapeutically effective amount of a Clostridial toxin to a peripheral location on the body of a patient. This peripheral location is other than the site on the body where the pain emanates.

Abstract: An intraocular lens implantable in an eye includes an optic for placement in the capsular bag of the eye and for directing light toward the retina of the eye. The optic has a central optical axis, an anterior face, an opposing posterior face and a peripheral edge between the faces. The peripheral edge has one or more curved or angled surfaces that reduce glare within the IOL. For instance, a rounded transition surface on the anterior side of the peripheral edge diffuses the intensity of reflected light, or a particular arrangement of straight edge surfaces refracts the light so as not to reflect, or does not reflect at all. The intersection of the peripheral edge and at least one of the anterior face and the posterior face, preferably both of such faces, forms a peripheral corner located at a discontinuity between the peripheral edge and the intersecting face or faces.

Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.

Abstract: An intraocular lens (IOL) insertion apparatus including a cartridge with an IOL-receiving chamber, a handpiece into which the cartridge is loaded, and a plunger rod that extends through a lumen in the cartridge to reliably engage the IOL therein. The chamber is stepped in one section to cause the IOL positioned therein to assume a complex curve. A lip or projection on the plunger rod is aligned with the complex curve and intersects the IOL to reliably engage the IOL across its thickness. The cartridge may be a folding type with a pair of arcuate walls and extension wings joined at a living hinge. The stepped section of the chamber may coincide with the location of the hinge.

Abstract: An intraocular lens having an optic and a plurality of fixation members coupled to the optic. The fixation members are adapted to be evenly circumferentially distributed about the anterior chamber to reduce the phenomenon of malshaping the iris, for example, pupil ovalling.

Abstract: Compounds having Formula 1 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.

Abstract: An iris-supported intraocular lens having an optic portion and a plurality of fixation members coupled thereto. Each fixation member has a pair of pincer arms that separate outward of the optic and converge toward one another at aligned end tips. One or both of the end tips are covered with a soft sleeve or cap. The IOL is fixed in the anterior chamber of the eye by pinching the iris tissue between the end tips of each pair of pincer arms. The soft sleeves eliminate damage to the iris tissue.

Abstract: An intraocular lens having an ultrathin and highly pliable optic and relatively more rigid fixation members extending outward therefrom. The optic desirably includes a flange to which a common arm of a pair of joined fixation members attaches. The fixation members extend on opposite sides of the optic in U-shaped flex portions spanning a distance larger than the diameter of the optic. The fixation members may be flexed inward so as to overlap within the diameter of the optic and define an insertion profile of less than about 5 mm. For anterior implantation, four relatively evenly circumferentially spaced pods are provided by the pair of fixation members. The optic center desirably has a thickness of less than about 0.5 mm for meniscus type optics, and may be made of silicone, hydrophilic acrylic, or hydrophobic acrylic. The fixation members have a thickness of about 0.25 mm and are desirably made of poly methyl methacrylate (PMMA) or polyether sulfone.

Abstract: Apparatus and methods for holding and packaging intracorneal implants are provided. In one embodiment, the apparatus includes a holder body having a surface sized and adapted to carry an intracorneal implant, and a through hole extending through the surface, preferably sized and adapted to facilitate suction being applied to the intracorneal implant located in proximity to the surface. A cap member preferably is provided and is sized and adapted to be secured to the holder body so as to hold an intracorneal implant between the surface of the body and the cap member. Methods for packaging intracorneal implants and for providing intracorneal implants ready for use are provided and may involve using such apparatus.